-

AbCellera to Present at Upcoming Investor Conferences in November

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

  • Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 3:50 p.m. Pacific Time (6:50 p.m. Eastern Time)
  • Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)

Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.

About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116

AbCellera Biologics Inc.

NASDAQ:ABCL

Release Summary
AbCellera to Present at Upcoming Investor Conferences in November
Release Versions
$Cashtags

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
More News From AbCellera Biologics Inc.

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026...

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Appoints Dr. Lynn Seely to its Board of Directors...

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

DUBLIN & VANCOUVER, British Columbia--(BUSINESS WIRE)--Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies...
Back to Newsroom